News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ERYtech Pharma Completes the Enrollment of Patients in Its Phase I Clinical Trial in Pancreatic Cancer



6/27/2011 9:56:44 AM

LYON, France & PHILADELPHIA--(BUSINESS WIRE)-- ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma. The first results in this study demonstrated that Graspa® was active, with a safety profile that was satisfactory for patients in last-line therapy. On the back of this success, ERYTECH is expecting to forge ahead with the clinical development of Graspa® for the treatment of pancreatic cancer in “responder” patients.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES